MedTrace Logo

NovellusDx Cancer Early Detection Blood Test- Clinical Trial

NCT01883388 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2018-03-29

No results posted yet for this study

Summary

NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, thus enabling early stage disease signature detection. The investigators' current clinical trial is focused on proving the main feature of NovellusDx's Early Detection Test- discriminating between cancer patients and healthy subjects.

Conditions

Sponsors & Collaborators

  • Fore Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Yishai Ofran, MD · Rambam MC. Haematology Department

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01883388 on ClinicalTrials.gov